Rostaporfin is a small molecule commercialized by Kintara Therapeutics, with a leading Phase II program in Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome). According to Globaldata, it is involved in 13 clinical trials, of which 10 were completed, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Rostaporfin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Rostaporfin is expected to reach an annual total of $2 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Rostaporfin (REM-001) is under development for the treatment of metastatic ovarian cancer, basal cell carcinoma with nevus syndrome, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer) and metastatic colon cancer. The drug candidate is a light-activated cytotoxic drug. It is administered through intravenous route. It is a new chemical entity (NCE).
It was also under development for the treatment of cutaneous metastatic breast cancer, metastatic lung cancer bile duct cancer, classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) and prevention of access graft disease in hemodialysis patients.
Kintara Therapeutics Overview
Kintara Therapeutics (DelMar) formerly DelMar Pharmaceuticals Inc, is a clinical stage drug development bio pharmaceutical company. It is engaged in the development and commercialization of new cancer therapies. The company offers VAL-083, a small molecule chemotherapy used for the treatment of refractory glioblastoma multiforme(GMB) of brain cancer. Kintara also explores VAL-083 as a therapy for solid tumors and front-line GBM including ovarian cancer and non-small cell lung cancer (NSCLC). The company offers its produts and services to lung cancer, ovarian cancer, chronic myeloid leukemia, brain cancers, and lung cancer. Kintara provides warrants services, pre-clinical testing, and clinical trials, among others. It also conducts research and development on cancer indications. It has operations in the US and Canada. Kintara Pharmaceuticals is headquartered in San Diego, California, United States.
The operating loss of the company was US$22.7 million in FY2022, compared to an operating loss of US$38.2 million in FY2021. The net loss of the company was US$22.7 million in FY2022, compared to a net loss of US$38.3 million in FY2021.
For a complete picture of Rostaporfin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.